Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
70860-0218-10 70860-0218 Cyclophosphamide Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 21, 2021 Aug. 31, 2024 In Use
70860-0219-20 70860-0219 decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 15, 2021 Dec. 31, 2024 In Use
70860-0223-61 70860-0223 Carmustine Carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous July 11, 2022 April 30, 2024 In Use
70860-0783-10 70860-0783 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 15, 2021 July 31, 2024 In Use
70860-0785-05 70860-0785 Palonosetron hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2022 Feb. 28, 2025 In Use
83257-0001-11 83257-0001 Trastuzumab-dkst OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 1, 2023 In Use
83257-0003-01 83257-0003 Trastuzumab-dkst OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 1, 2023 In Use
00338-9581-02 00338-9581 Doxorubicin hydrochloride Doxorubicin hydrochloride, Liposomal 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 19, 2023 In Use
10702-0361-99 10702-0361 Carmustine Carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous March 1, 2024 In Use
25021-0248-51 25021-0248 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0249-51 25021-0249 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0255-05 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-17 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-50 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
39822-0250-01 39822-0250 Cyclophosphamide CYCLOPHOSPHAMIDE 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Dec. 19, 2023 In Use
39822-0255-01 39822-0255 Cyclophosphamide CYCLOPHOSPHAMIDE 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Dec. 19, 2023 In Use
39822-0260-01 39822-0260 Cyclophosphamide CYCLOPHOSPHAMIDE 2.0 g/150mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Dec. 19, 2023 In Use
55150-0270-01 55150-0270 Cyclophosphamide Cyclophosphamide 500.0 mg/2.5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 25, 2021 In Use
55150-0270-99 55150-0270 Cyclophosphamide Cyclophosphamide 500.0 mg/2.5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 20, 2023 In Use
55150-0271-01 55150-0271 Cyclophosphamide Cyclophosphamide 1.0 g/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 25, 2021 In Use
55150-0271-99 55150-0271 Cyclophosphamide Cyclophosphamide 1.0 g/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 20, 2023 In Use
55150-0272-01 55150-0272 Cyclophosphamide Cyclophosphamide 2.0 g/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 20, 2023 In Use
68001-0608-24 68001-0608 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 1, 2024 In Use
68001-0609-33 68001-0609 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 1, 2024 In Use
68083-0233-06 68083-0233 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 3, 2024 In Use
68083-0388-01 68083-0388 Dexrazoxane for Injection Dexrazoxane 250.0 mg/25mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 16, 2019 In Use
71288-0171-11 71288-0171 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
71288-0172-21 71288-0172 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
72205-0171-07 72205-0171 ARSENIC TRIOXIDE ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 6, 2024 In Use
72205-0172-07 72205-0172 ARSENIC TRIOXIDE ARSENIC TRIOXIDE 2.0 mg/2mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb. 6, 2024 In Use
82650-0144-01 82650-0144 PALONOSETRON HYDROCHLORIDE Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 23, 2018 In Use
82943-0100-03 82943-0100 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 1, 2024 In Use
82943-0101-05 82943-0101 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 1, 2024 In Use
83090-0009-01 83090-0009 Arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83090-0009-10 83090-0009 Arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83090-0010-01 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83090-0010-10 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83634-0202-61 83634-0202 Melphalan hydrochloride Melphalan Hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 18, 2023 In Use
83634-0776-10 83634-0776 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 28, 2024 In Use
72579-0121-01 72579-0121 Tislelizumab TEVIMBRA 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous March 14, 2024 In Use
73776-0001-12 73776-0001 Lifileucel AMTAGVI 72000000000.0 1/500mL Immunotherapy Tumor Infiltrating Lymphocytes (TILs) CD4+T, CD8+T Intravenous Feb. 16, 2024 In Use
55513-0005-01 55513-0005 Darbepoetin alfa Aranesp 100.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0005-04 55513-0005 Darbepoetin alfa Aranesp 100.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0027-01 55513-0027 Darbepoetin alfa Aranesp 150.0 ug/.3mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Feb. 18, 2011 In Use
55513-0027-04 55513-0027 Darbepoetin alfa Aranesp 150.0 ug/.3mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
00143-9558-01 00143-9558 Levoleucovorin Levoleucovorin 50.0 mg/5mL Ancillary Therapy Chemoprotective Antidote Intravenous July 7, 2016 In Use
70121-1099-01 70121-1099 Levoleucovorin Levoleucovorin 50.0 mg/1 Ancillary Therapy Chemoprotective Antidote Intravenous Feb. 13, 2017 In Use
00338-1305-01 00338-1305 Mesna Mesnex 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 30, 1988 In Use
00338-1305-03 00338-1305 Mesna Mesnex 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 30, 1988 In Use
00069-0107-01 00069-0107 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 10, 2011 Dec. 31, 2017 No Longer Used
00069-0109-01 00069-0109 Pamidronate Disodium Pamidronate Disodium 9.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 10, 2011 Dec. 31, 2017 No Longer Used
00069-0186-01 00069-0186 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 10, 2011 Dec. 31, 2017 No Longer Used
73042-0201-01 73042-0201 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Nov. 25, 2020 In Use
74527-0022-02 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan. 15, 2021 In Use
74527-0022-03 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan. 15, 2021 In Use
00069-0238-01 00069-0238 Rituximab-pvvr Ruxience 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 23, 2020 In Use
00069-0249-01 00069-0249 Rituximab-pvvr Ruxience 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 23, 2020 In Use
00069-0315-01 00069-0315 Bevacizumab-bvzr Zirabev 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
00069-0342-01 00069-0342 Bevacizumab-bvzr Zirabev 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
00703-3216-01 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 25, 2020 In Use
00703-3216-81 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3217-01 00703-3217 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3213-01 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3213-81 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3218-01 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3218-81 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00338-0063-01 00338-0063 doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 13, 2019 In Use
73462-0101-01 73462-0101 Trilaciclib Cosela 300.0 mg/20mL Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Intravenous Feb. 12, 2021 In Use
00069-0308-01 00069-0308 trastuzumab-qyyp Trazimera 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous March 10, 2021 In Use
00143-9606-01 00143-9606 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous June 8, 2020 In Use
00338-0080-01 00338-0080 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 15, 2019 In Use
00338-0086-01 00338-0086 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 15, 2019 In Use
00703-3071-01 00703-3071 Romidepsin Romidepsin 5.0 mg/mL Chemotherapy Enzyme Inhibitor HDAC Intravenous April 14, 2020 In Use
00703-4004-01 00703-4004 Romidepsin Romidepsin 5.0 mg/mL Chemotherapy Enzyme Inhibitor HDAC Intravenous April 14, 2020 In Use
16714-0137-01 16714-0137 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 25, 2021 In Use
16714-0927-01 16714-0927 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 8, 2019 In Use
16729-0351-92 16729-0351 busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous July 22, 2019 In Use
39822-2100-02 39822-2100 dactinomycin dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous July 31, 2019 In Use
00591-4385-79 00591-4385 fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 19, 2019 In Use
16714-0120-01 16714-0120 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 16, 2020 In Use
16714-0929-01 16714-0929 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 20, 2020 In Use
00143-9384-01 00143-9384 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 8, 2020 In Use
00338-0008-01 00338-0008 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
50242-0051-10 50242-0051 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous June 3, 2019 In Use
50242-0051-21 50242-0051 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov. 26, 1997 In Use
50242-0103-01 50242-0103 polatuzumab vedotin POLIVY 30.0 mg/1.88mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Sept. 18, 2020 In Use
50242-0132-01 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb. 10, 2017 In Use
50242-0132-10 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 3, 2019 In Use
50242-0917-01 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 18, 2016 In Use
50242-0917-86 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Aug. 11, 2016 In Use
16714-0001-01 16714-0001 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 22, 2021 In Use
43598-0859-11 43598-0859 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 6, 2019 In Use
43598-0948-11 43598-0948 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous July 1, 2020 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 28, 2019 In Use
55513-0224-01 55513-0224 rituximab-arrx Riabni 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0326-01 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
68001-0480-22 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68001-0480-35 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68083-0381-01 68083-0381 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use

Found 10,000 results in 9 milliseconds — Export these results